南京高科股份有限公司 本人陈莹，女，1977 年 12 月生，汉族，江苏泰州人，中共党员， 管理科学与工程（金融工程方向）博士。曾任南京大学工程管理学院 讲师、副教授等职。现任南京大学工程管理学院教授、博士生导师， 南京大学金融科技研究与发展中心主任，证标委金融科技专委会委员， 江苏省区块链标准委员会秘书长，江苏吉鑫风能科技股份有限公司、 江苏联环药业股份有限公司独立董事。 独立董事陈莹 2024 年度述职报告 本人于 2024 年 8 月当选为南京高科股份有限公司（以下简称"公 司"）第十一届董事会的独立董事，在任职期间严格按照《公司法》 《上市公司独立董事管理办法》《上市公司治理准则》《公司章程》及 《独立董事制度》等相关法律法规和规章制度的规定和要求，在 2024 年度，忠实、勤勉、尽责地履行职责，积极出席公司召开的相关会议， 认真审议董事会的各项议案，独立、客观、公正地对各项议案和相关 事项发表独立意见，充分发挥了独立董事的独立性、专业性的作用， 切实维护了公司和全体股东尤其是中小股东的合法权益。现将 2024 年度履行职责情况报告如下： 一、个人基本情况 本人通过进行独立董事独立性情况年度自查，符合 ...

南京高科股份有限公司 独立董事冯巧根 2024 年度述职报告 本人冯巧根，作为南京高科股份有限公司（以下简称"公司"） 第十届董事会的独立董事，在任职期间严格按照《公司法》《上市公 司独立董事管理办法》《上市公司治理准则》等法律法规、规范性文 件以及《公司章程》《独立董事制度》《独立董事年报工作制度》等公 司制度的规定和要求，认真、勤勉、独立地履行职责，积极出席相关 会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员 会委员的作用，切实维护了公司和全体股东的利益。 报告期内，公司董事会进行了换届选举，因任期届满，本人自 2024 年 8 月 11 日起不再继续担任公司独立董事。现将本人 2024 年 任职期间（2024 年 1 月 1 日至 2024 年 8 月 11 日）的主要工作情况 报告如下： 一、个人基本情况 本人冯巧根，男，1961 年出生，经济学博士，管理学博士后， 九三学社社员。曾任浙江工商大学会计学院副院长、湖南大学会计学 院副院长、教授、博士生导师，浙江省第九届政协委员，浙江省注册 会计师协会理事等职。现任南京大学商学院教授、博士生导师，江苏 新泉汽车饰件股份有限公司、苏豪弘业股份 ...

报告期内，公司董事会进行了换届选举，因任期届满，本人自 2024 年 8 月 11 日起不再继续担任公司独立董事。现将本人 2024 年 任职期间（2024 年 1 月 1 日至 2024 年 8 月 11 日）的主要工作情况 报告如下： 南京高科股份有限公司 独立董事夏江 2024 年度述职报告 本人在任职南京高科股份有限公司（以下简称"公司"）的独立 董事期间，严格按照《公司法》《上市公司独立董事管理办法》《上市 公司治理准则》《公司章程》及《独立董事制度》等相关法律法规和 规章制度的规定和要求，在 2024 年度，忠实、勤勉、尽责地履行职 责，积极出席公司召开的相关会议，认真审议董事会的各项议案，独 立、客观、公正地对各项议案和相关事项发表独立意见，充分发挥了 独立董事的独立性、专业性的作用，切实维护了公司和全体股东尤其 是中小股东的合法权益。 一、个人基本情况 夏江，男，1963 年出生，现任南京大学经济学系副教授、硕士 研究生导师。主要从事资本市场、证券投资、房地产投资等方面的教 学和研究工作，拥有多项执业资格认证。参加过省内多家国有企业改 制、上市公司的企业发展战略研究工作。2000 年至 200 ...

南京高科股份有限公司 独立董事高波 2024 年度述职报告 本人作为南京高科股份有限公司（以下简称"公司"）独立董事， 严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立 董事管理办法》等法律法规、规范性文件以及《公司章程》《独立董 事制度》《独立董事年报工作制度》的规定和要求，忠实、诚信、勤 勉尽责地履行独立董事职责和义务，及时关注公司的经营及发展状况， 按时出席 2024 年度召开的各次董事会、股东会及其他相关会议，充 分发挥独立董事的作用，有效地维护公司、全体股东尤其是中小股东 的合法权益。 报告期内，公司董事会进行了换届选举，因任期届满，本人自 2024 年 8 月 11 日起不再继续担任公司独立董事。现将本人 2024 年 任职期间（2024 年 1 月 1 日至 2024 年 8 月 11 日）的主要工作情况 报告如下： 一、个人基本情况 高波，男，1962 年出生，博士，经济学教授。现任南京大学商 学院教授、博士生导师，南京大学城市与不动产研究中心主任，国家 教育部重点研究基地—南京大学长江三角洲经济社会发展研究中心 教授，江苏省三三三人才工程中青年科技领军人才，（中国）消费经 济学 ...

本人通过进行独立董事独立性情况年度自查，符合中国证监会 《上市公司独立董事管理办法》中关于独立性的规定，不存在任何影 响独立性的情形，并已将自查情况报告提交公司董事会。 二、年度履职概况 （一）出席董事会、股东会情况 2024 年，公司董事会召开会议 7 次，本人应参加会议 4 次，亲 1 南京高科股份有限公司 独立董事范从来 2024 年度述职报告 本人于 2024 年 8 月当选为南京高科股份有限公司（以下简称"公 司"）第十一届董事会的独立董事，在任职期间严格按照《公司法》 《上市公司独立董事管理办法》《上市公司治理准则》等法律法规、 规范性文件以及《公司章程》《独立董事制度》《独立董事年报工作制 度》等公司制度的规定和要求，认真、勤勉、独立地履行职责，积极 出席相关会议，认真审议董事会各项议案，充分发挥了独立董事及各 专门委员会委员的作用，切实维护了公司和全体股东的利益。现将本 人 2024 年度履行独立董事职责情况汇报如下： 一、个人基本情况 本人范从来，男，1962 年 9 月生，汉族，江苏南通人，中共党 员，博士研究生学历，教育部长江学者特聘教授。曾任南京大学经济 系主任、商学院副院长、党委书记 ...

Financial Performance - The company's operating revenue for Q1 2025 reached ¥1,059,709,613.12, a significant increase of 274.89% compared to ¥282,671,547.56 in the same period last year[5] - Net profit attributable to shareholders was ¥692,136,216.19, reflecting a year-on-year growth of 31.62% from ¥525,847,297.99[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥736,255,629.82, up 33.32% from ¥552,258,612.19 in the previous year[5] - The basic earnings per share increased to ¥0.400, a rise of 31.58% compared to ¥0.304 in the same period last year[5] - The weighted average return on equity improved to 3.63%, an increase of 0.68 percentage points from 2.95%[5] - Total operating revenue for Q1 2025 reached ¥1,061,048,907.30, a significant increase from ¥283,631,767.74 in Q1 2024, representing a growth of approximately 274%[21] - Net profit for Q1 2025 was ¥699,858,259.96, compared to ¥525,421,831.66 in Q1 2024, indicating an increase of about 33%[22] - Operating profit for Q1 2025 was ¥702,797,666.62, up from ¥497,869,998.62 in Q1 2024, reflecting a growth of approximately 41%[22] - Total investment income for Q1 2025 was ¥681,930,929.89, compared to ¥588,702,468.93 in Q1 2024, representing an increase of about 16%[22] Cash Flow - The net cash flow from operating activities was ¥43,225,859.51, a significant recovery from a negative cash flow of ¥389,468,188.39 in the same period last year[5] - Cash flow from operating activities for Q1 2025 was ¥43,225,859.51, a turnaround from a negative cash flow of ¥389,468,188.39 in Q1 2024[23] - The company reported a net cash inflow from financing activities of ¥519,777,239.35 in Q1 2025, compared to ¥250,410,416.60 in Q1 2024, indicating a growth of approximately 107%[24] - The net cash flow from financing activities improved to 244,662,010.60 RMB in Q1 2025, compared to -273,252,011.46 RMB in Q1 2024[35] - Total cash inflow from operating activities in Q1 2025 was 291,366,789.11 RMB, up from 199,040,100.55 RMB in Q1 2024, representing an increase of approximately 46.4%[34] - Cash outflow from operating activities increased to 406,558,868.55 RMB in Q1 2025, compared to 180,871,438.98 RMB in Q1 2024, marking an increase of about 124.5%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥39,308,403,898.07, representing a 2.38% increase from ¥38,395,047,667.66 at the end of the previous year[5] - The company's total current assets as of March 31, 2025, amounted to 17.21 billion yuan, compared to 16.79 billion yuan at the end of 2024[16] - The company's total liabilities as of March 31, 2025, were 18.84 billion yuan, up from 18.42 billion yuan at the end of 2024[18] - The company's total assets increased to CNY 27.12 billion as of March 31, 2025, compared to CNY 26.20 billion at the end of 2024, reflecting a growth of approximately 3.5%[25] - The company's total equity increased to CNY 17.38 billion as of March 31, 2025, compared to CNY 16.99 billion at the end of 2024, reflecting a growth of about 2.3%[27] Sales and Market Activity - The company attributed the revenue growth primarily to increased sales from real estate development projects[7] - In Q1 2025, the company achieved a contract sales area of 42,800 square meters, a year-on-year increase of 6014.29%[12] - The contract sales amount reached 449.30 million yuan, reflecting a year-on-year growth of 1214.79%[12] - The company has not reported any significant new product developments or market expansions during this quarter[5] - The company has no new real estate projects or construction activities in Q1 2025[12] Shareholder Information - The company is actively addressing the remaining frozen shares related to a legal dispute, with 141,193,607 shares still frozen, accounting for 23.49% of its holdings[15] - The company reported a significant increase in accounts receivable, which rose to 974.82 million yuan from 705.08 million yuan[17] - The company’s equity attributable to shareholders increased to 19.29 billion yuan from 18.81 billion yuan[19] Research and Development - Research and development expenses increased to ¥9,297,234.40 in Q1 2025 from ¥2,180,198.29 in Q1 2024, marking a rise of about 326%[21]

Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of CNY 1,725,229,897.01, an increase of 10.58% compared to CNY 1,560,145,875.01 in 2023[6]. - The company's operating revenue for 2024 was CNY 1,975,445,403.11, representing a decrease of 58.21% from CNY 4,726,511,629.41 in 2023[22]. - The net profit attributable to the parent company was CNY 1,725.23 million, reflecting a year-on-year growth of 10.58%[32]. - The company achieved a basic earnings per share of CNY 0.997 in 2024, representing a 10.53% increase compared to CNY 0.902 in 2023[23]. - The company reported a weighted average return on equity of 9.47%, an increase of 0.29 percentage points from 9.18% in the previous year[23]. - The net profit attributable to the listed company, excluding non-recurring gains and losses, for 2024 is approximately ¥1.62 billion, a decrease of 1.54% compared to ¥1.65 billion in 2023[194]. Cash Flow and Assets - The net cash flow from operating activities was negative CNY 500,820,614.84, an improvement from negative CNY 2,177,480,214.41 in the previous year[22]. - The total assets at the end of 2024 were CNY 38,395,047,667.66, a 2.98% increase from CNY 37,283,181,671.10 at the end of 2023[22]. - The company's asset-liability ratio at the end of the reporting period was 47.97%, with interest-bearing liabilities totaling 9.5 billion yuan, accounting for 24.74% of total assets[36]. - The current ratio improved slightly to 1.17 in 2024 from 1.16 in 2023, while the quick ratio decreased by 5.38% to 0.39[194]. - The debt-to-asset ratio decreased to 47.97% in 2024 from 50.24% in 2023, reflecting a reduction of 4.50%[194]. Dividends and Retained Earnings - The company plans to distribute a cash dividend of CNY 3 per 10 shares, totaling CNY 519,101,893.20, subject to shareholder approval[6]. - The retained earnings available for distribution to shareholders for 2024 amounted to CNY 12,791,290,611.56 after accounting for previous year’s dividends[6]. - The cash dividend for the fiscal year 2023 represents 30.09% of the net profit attributable to ordinary shareholders, which is approximately 1.73 billion RMB[134]. - The cumulative cash dividends over the last three fiscal years amount to approximately 1.73 billion RMB, with an average cash dividend payout ratio of 91.27%[136]. Business Segments and Revenue Sources - The real estate business recorded a contract sales area of 18,700 square meters, a significant decrease of 92.66% year-on-year[33]. - The contract sales amount for the real estate sector was CNY 620.31 million, down 67.59% compared to the previous year[33]. - The municipal business generated revenue of CNY 1,153.73 million, a decrease of 5.67% year-on-year[34]. - The revenue from the pharmaceutical sales segment reached CNY 264,427,648.89, marking a new addition to the company's revenue streams[49]. - The company's main revenue sources for 2024 included real estate development sales, generating approximately ¥197.54 million[200]. Investment and Future Plans - The company plans to gradually exit the real estate business over the next 3-5 years, focusing on high-tech industry investments[35]. - The company invested in three new projects in the high-tech sector, including DiNuoWeiHua and RuiChu Pharmaceutical[35]. - The company aims to strengthen its core business in equity investment and develop the biopharmaceutical industry as a main transformation direction[89]. - The company plans to enhance project sales and cash flow management in its real estate business while gradually exiting real estate development[90]. Risk Management - The company has identified various risks including macroeconomic, business development, investment management, and financial risks in its future outlook[9]. - The company has been actively managing risks for eight consecutive years, with a focus on risk prevention and resolution, particularly in light of macroeconomic conditions and industry trends[96]. - The company’s future plans and strategies are subject to investment risks and do not constitute a commitment to investors[7]. Environmental and Social Responsibility - The company has invested approximately 34.09 million RMB in environmental protection during the reporting period[141]. - The new wastewater treatment plant has a designed processing capacity of 60,000 tons per day, with pollutant discharge limits set at COD ≤ 766.5 tons/year and ammonia nitrogen ≤ 61.32 tons/year, with no exceedances reported during the reporting period[144]. - The company has committed to social responsibility, with a total investment of 8.01 million yuan in public welfare projects, including support for new employment groups[151]. Management and Governance - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 686.19 million CNY[105]. - The company has established a performance assessment and remuneration management implementation method for the years 2023-2025[113]. - The company has implemented a comprehensive governance structure, enhancing compliance and operational transparency to protect shareholder rights and promote sustainable development[100]. - The company has a diverse management team with backgrounds in finance, engineering, and economics, enhancing its strategic capabilities[106]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 45,355, an increase from 43,574 at the end of the previous month[171]. - The largest shareholder, Nanjing New Port Development Co., Ltd., holds 601,083,220 shares, representing 34.74% of the total shares, with 229,000,000 shares frozen[173]. - The company has not engaged in any share buybacks during the reporting period[182].

公司代码：600064 公司简称：南京高科 南京高科股份有限公司 2024年度内部控制评价报告 南京高科股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下 简称"企业内部控制规范体系"），结合本公司（以下简称"公司"）内部控制制度和评价 办法，在内部控制日常监督和专项监督的基础上，我们对公司2024年12月31日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制 进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、 监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对 报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息 真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性， 故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能 ...

南京高科股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号—规 范运作》《国有企业、上市公司选聘会计师事务所管理办法》和南京 高科股份有限公司（以下简称"公司"）的《公司章程》《董事会审计 委员会工作细则》等规定和要求，公司董事会审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职。现将对会计师事务所 2024 年度履 职评估及履行监督职责的情况汇报如下： 一、会计师事务所基本情况 （一）基本信息 天衡会计师事务所（特殊普通合伙）（以下简称"天衡"）前身为 1985 年成立的江苏会计师事务所，1999 年脱钩改制，2013 年转制为 特殊普通合伙会计师事务所，于 2013 年 9 月 28 日取得江苏省财政厅 颁发的会计师事务所执业证书，长期从事证券服务业务，是中国首批 获得证券期货相关业务资格和首批取得金融企业审计资格的会计师 事务所之一。 截至 2024 年末，天衡拥有合伙人 85 名、注册会计师 386 名，签 署过证券服务业务审计报告的注册会计师 227 ...

一、资质条件 （一）基本信息 天衡前身为 1985 年成立的江苏会计师事务所，1999 年脱钩改制， 2013 年转制为特殊普通合伙会计师事务所，于 2013 年 9 月 28 日取 得江苏省财政厅颁发的会计师事务所执业证书，长期从事证券服务业 务，是中国首批获得证券期货相关业务资格和首批取得金融企业审计 资格的会计师事务所之一。 截至 2024 年末，天衡拥有合伙人 85 名、注册会计师 386 名，签 署过证券服务业务审计报告的注册会计师 227 名，是国内最具综合实 力的会计师事务所之一。 （二）投资者保护能力 截至 2024 年末，天衡已提取职业风险基金 2,445.10 万元，购买 的职业保险累计赔偿限额为 10,000.00 万元，相关职业保险能够覆盖 因审计失败导致的民事赔偿责任。近三年不存在因执业行为在相关民 事诉讼中承担民事责任的情况。 1 （三）诚信记录 南京高科股份有限公司 2024 年度会计师事务所履职情况评估报告 南京高科股份有限公司（以下简称"公司"）聘请天衡会计师事 务所（特殊普通合伙）（以下简称"天衡"）作为公司 2024 年度财务 报告审计机构、内部控制审计机构。根据财政部、 ...